PRESS RELEASE published on 04/17/2026 at 21:00, 2 months 8 days ago Informations privilégiées / Autres communiqués Innate Pharma présentera des résultats intermédiaires de l'essai de Phase 2 MATISSE évaluant IPH5201 lors d'une session plénière dédiée aux essais cliniques au congrès de l'AACR 2026 Essai Clinique Cancer Du Poumon Innate Pharma AACR 2026 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 2 months 8 days ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
BRIEF published on 04/13/2026 at 07:05, 2 months 13 days ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 2 months 13 days ago Innate Pharma : Mise à Jour du Capital et des Droits de Vote Droits De Vote Biotechnologie Actions Immunothérapie Innate Pharma
BRIEF published on 04/13/2026 at 07:05, 2 months 13 days ago Innate Pharma met à jour ses actions et ses droits de vote à compter d'avril 2026 Biotechnologie Innate Pharma Actions Et Droits De Vote Avril 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 2 months 13 days ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 2 months 13 days ago Informations privilégiées / Autres communiqués Innate Pharma a publié le nouveau nombre d'actions et de droits de vote au 9 avril 2026 conformément aux règlements de l'AMF. Découvrez les détails dans le communiqué de presse Droits De Vote Actions AMF Communiqué De Presse Innate Pharma
PRESS RELEASE published on 04/13/2026 at 07:00, 2 months 13 days ago Inside Information / Other news releases Innate Pharma to hold its Annual General Meeting of shareholders on May 21, 2026 at 10:30 a.m. CEST in Marseille. Shareholders must register shares by May 14, 2026, 00:00 Paris time, to attend Annual General Meeting Shareholders Registration Innate Pharma Marseille
PRESS RELEASE published on 04/13/2026 at 07:00, 2 months 13 days ago Inside Information / Other news releases Innate Pharma releases total shares and voting rights as of April 9, 2026, in compliance with French regulations. Learn about its innovative immunotherapies for cancer patients Voting Rights Shares French Regulations Innate Pharma Immunothérapies
BRIEF published on 04/03/2026 at 07:05, 2 months 23 days ago Innate Pharma to Join Kempen Life Sciences Conference Biotechnology Investor Meetings Innate Pharma Cancer Immunotherapies Kempen Conference
Published on 06/26/2026 at 14:05, 2 hours 36 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 41 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 41 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 56 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 1 hour 11 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 18 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 19 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 9 hours 41 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 41 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
